The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial

Cuttino, L.W.; McCall, Linda; Kubicky, Charlotte Dai; Ballman, Karla V.; Le-Petross, Huong T.; Hunt, Kelly K.; Haffty, Bruce G.; Rosenkranz, Kari M.; Boughey, Judy C.

doi:10.1016/j.ijrobp.2021.09.054

Cited by 10 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of patients successfully completed radiation with protocol adherent plans that included whole breast radiation and a boost to all lumpectomy sites (195 of the 236 patients enrolled). 12 Higher absolute radiation boost volume was associated with higher rates of grade 21 acute dermatitis although relative boost volume was not. Neither absolute nor relative boost volume were associated with worse overall cosmesis.…”

Section: Discussionmentioning

confidence: 93%

“…A boost of 10-16 Gy in 2.0-Gy daily fractions to each tumor bed was mandatory. 12 The protocol required that $90% of the lumpectomy planning target volume receive $90% of the boost prescription dose. Not more than 50% of the target breast tissue was to receive over 60 Gy.…”

Section: Methodsmentioning

confidence: 99%

“…AFFILIATIONS 1 Mayo Clinic, Rochester, MN 2 Dartmouth Hitchcock Medical Center, Dartmouth College-Norris Cotton Cancer Center, Lebanon, NH 3 Alliance Statistics and Data Management Center, Weill Cornell Medicine, New York, NY 4 Alliance Statistics and Data Management Center, Duke University, Durham, NC 5 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 6 Sarah Cannon Cancer Center, Richmond, VA 7 Oregon Health and Science University, Legacy Good Samaritan Hospital and Medical Center, Portland, OR 8 University of Texas MD Anderson Cancer Center, Houston, TX 9 Cedars-Sinai Medical Center, Los Angeles, CA 10 Memorial Sloan Kettering Cancer Center, New York, NY 11 Alliance for Clinical Trials in Oncology Operations Office, Chicago, IL 12 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 13 Dana-Farber/Partners Cancer Care, Boston, MA…”

Section: Corresponding Authormentioning

confidence: 99%

“…We have previously reported secondary end points of this trial, including the conversion to mastectomy rate, cosmetic outcome, and radiation feasibility. [10][11][12] The primary end point for this trial is LR as a first event. LR is defined as histologic evidence of ductal carcinoma in situ (DCIS) or invasive BC in the ipsilateral breast or chest wall.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Boughey

Rosenkranz

Ballman

et al. 2023

JCO

Self Cite

View full text Add to dashboard Cite

PURPOSE Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible. Patients underwent lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds. The primary end point was cumulative incidence of local recurrence (LR) at 5 years with an a priori rate of clinical acceptability of <8%. RESULTS Among 270 women enrolled between November 2012 and August 2016, there were 204 eligible patients who underwent protocol-directed BCT. The median age was 61 years (range, 40-87 years). At a median follow-up of 66.4 months (range, 1.3-90.6 months), six patients developed LR for an estimated 5-year cumulative incidence of LR of 3.1% (95% CI, 1.3 to 6.4). Patient age, number of sites of preoperative biopsy–proven BC, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories were not associated with LR risk. Exploratory analysis showed that the 5-year LR rate in patients without preoperative magnetic resonance imaging (MRI; n = 15) was 22.6% compared with 1.7% in patients with a preoperative MRI (n = 189; P = .002). CONCLUSION The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year LR rate for MIBC. This evidence supports BCT as a reasonable surgical option for women with two to three ipsilateral foci, particularly among patients with disease evaluated with preoperative breast MRI.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

Section: Corresponding Authormentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Boughey

Rosenkranz

Ballman

et al. 2023

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is essential to have histopathological examination and immunohistochemistry of all tumors. Radiopaque marking of the surgical bed of all excised lesions will be necessary; of note, in the ACOSOG Z11102 project (Alliance), good tolerance of the gland was documented when more than one surgical bed was irradiated with RT boost 19 .…”

Section: Bcsmentioning

confidence: 99%

Mexican breast cancer consensus. Management of early breast cancer

Bargalló-Rocha,

Aguilar-Villanueva,

Ahumada-Pámanes

et al. 2024

GAMO

View full text Add to dashboard Cite

Breast cancer, in early stages, has specific surgical, radiotherapy, and systemic management. This type of cancer includes ductal carcinoma in situ and breast cancers in stages I, IIA, IIB, and IIIA. This tenth update of the Mexican Breast Cancer Consensus addressed the management of early stages. The dissemination of this consensus contributes to the updating and homogeneity of breast cancer management criteria. This article aims to present the update in the multidisciplinary management of breast cancer.

show abstract

Breast Conservation Surgery

van den Bruele,

Rosenberger

2024

Illustrative Handbook of General Surgery

View full text Add to dashboard Cite

The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial

Cited by 10 publications

References 28 publications

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)

Mexican breast cancer consensus. Management of early breast cancer

Breast Conservation Surgery

Contact Info

Product

Resources

About